Viridian Therapeutics (VRDN) Q1 2026 earnings summary

Executive summary

• Focused on developing best-in-class medicines for serious and rare diseases, with a pipeline targeting autoimmune and rare diseases, including TED and Graves' disease.

• Launch preparations for veligrotug in TED are complete, with a PDUFA target action date of June 30, 2026, and EMA review underway.

• Advanced clinical programs for veligrotug (IV) and elegrobart (subcutaneous) for TED, with positive phase 3 data and regulatory submissions progressing.

• FcRn inhibitor portfolio advancing, including VRDN-006 and VRDN-008, with development milestones and early clinical data expected in 2026.

• Additional pipeline includes a TSHR inhibitor program with IND submission planned for Q4 2026.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $762.2 million as of March 31, 2026, down from $874.7 million at year-end 2025.

• Net loss for Q1 2026 was $104.9 million, compared to $86.9 million in Q1 2025.

• Research and development expenses were $77.6 million, and selling, general and administrative expenses were $38.7 million for Q1 2026, both increased year-over-year due to launch preparations.

• License and collaboration revenue for Q1 2026 was $0.1 million each; no product sales revenue generated to date.

Outlook and guidance

• Current cash and equivalents expected to fund operations for at least twelve months from the reporting date.

• Anticipates BLA submission for elegrobart in Q1 2027, aiming to be the first subcutaneous autoinjector for TED.

• Ongoing development of additional pipeline candidates and expansion of commercial capabilities.

• IND submission for TSHR program expected in Q4 2026, with clinical potential in TED and Graves' disease.

• VRDN-006 development plan and VRDN-008 phase 1 data expected in 2026.